著者

Ittetsu Tanaka Mitsushi Okazawa Masami Taniguchi Kenichiroh Suzuki Ryouji Tamura Hiroki Sakakibara Susumu Suetsugu

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.49, no.4, pp.269-273, 2000 (Released:2006-03-16)

参考文献数

29

被引用文献数

2

---

A 49-year-old Japanese man with bronchial asthma was admitted to hospital because of acute lobar pneumonia. A diagnosis of acute tuberculous pneumonia was made based on the pathologic findings of lung biopsy specimens and bacteriologic examination. For the 5 years before the onset of pneumonia, the patient had been treated with inhaled beclomethasone dipropionate (600 µg/day) and was well controlled. Laboratory findings revealed no immunosuppressive conditions, nor had the patient used oral corticosteroids for the treatment of his asthma. A tuberculin skin test had been negative approximately 30 years ago and annual chest X-ray examination had shown no evidence of tuberculosis over the past 5 years. Fiberoptic broncoscopic examination showed no evidence of bronchial tuberculosis or perforated lymph nodes. Because acute tuberculous lobar pneumonia in the lower lung field is rare, except in patients receiving oral corticosteroids or with immunodeficiency conditions, in this patient the inhalation of corticosteroids may have predisposed him to the onset of this condition.

著者

Takao Fujisawa Terufumi Shimoda Keisuke Masuyama Kimihiro Okubo Kohei Honda Mitsuhiro Okano Toshio Katsunuma Atsuo Urisu Yasuto Kondo Hiroshi Odajima Kazuyuki Kurihara Makoto Nagata Masami Taniguchi Shoichiro Taniuchi Satoru Doi Tomoshige Matsumoto Shoji Hashimoto Akihiko Tanaka Kensuke Natsui Nahoko Abe Hideki Ozaki

出版者

Japanese Society of Allergology

雑誌

Allergology International (ISSN:13238930)

巻号頁・発行日

vol.67, no.3, pp.347-356, 2018 (Released:2018-07-28)

参考文献数

49

被引用文献数

7

---

Background: To evaluate the long-term safety of subcutaneous immunotherapy with TO-204, a standardized house dust mite (HDM) allergen extracts, we conducted a multicenter, open label clinical trial.Methods: Japanese patients aged 5-65 years were eligible for the study, if they had HDM-induced allergic rhinitis (AR), allergic bronchial asthma (BA), or both. TO-204 was administered in a dose titration scheme, and the maintenance dose was determined according to the predefined criteria. The treatment period was 52 weeks, and patients who were willing to continue the treatment received TO-204 beyond 52 weeks. This clinical trial is registered at the Japan Pharmaceutical Information Center (Japic CTI-121900).Results: Between July 2012 and May 2015, 44 patients (28 with AR and 16 with allergic BA) were enrolled into the study. All patients were included in the analysis. The duration of treatment ranged from 23 to 142 weeks and the median maintenance dose was 200 Japanese allergy units (JAU). Adverse events occurred in 22 patients (50%). The most common adverse event was local reactions related to the injection sites. Four patients experienced anaphylactic reactions when they were treated with the dose of 500 JAU. Two patients experienced anaphylactic shock with the doses of 1000 JAU at onset. These 6 patients could continue the study with dose reduction.Conclusions: Safety profile of TO-204 was acceptable in Japanese patients with HDM-induced AR or allergic BA. Higher doses should be administered carefully, because the risk of anaphylaxis increased at doses of 500 or 1000 JAU.